TLSI
TriSalus Life Sciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
TriSalus Life Sciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
No changes.
No changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of TriSalus Life Sciences, Inc.'s 3 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of TriSalus Life Sciences, Inc.'s 3 closest co-movers, none share that code.
TriSalus Life Sciences, Inc.
3.64
pre 3.48 −4.14%
—
—
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| First Light | $29.8M | 30.11% | +29.32% |
| BlackRockindex-like | $12.1M | 12.22% | +77.33% |
| Vanguardindex-like | $7.9M | 7.95% | +28.38% |
| Cerity Partners | $7.3M | 7.37% | +103.68% |
| Geodeindex-like | $5.4M | 5.47% | +53.14% |
| Manager | Value | % base | |
|---|---|---|---|
| First Light | $29.8M | 30.11% | +29.32% |
| BlackRockindex-like | $12.1M | 12.22% | +77.33% |
| Vanguardindex-like | $7.9M | 7.95% | +28.38% |
| Cerity Partners | $7.3M | 7.37% | +103.68% |
| Geodeindex-like | $5.4M | 5.47% | +53.14% |
Tall tick = annual report · Source: EDGAR
Bull1
Bear2
Expected move
No implied move.